Classification of neuroleptics--zotepine.
Neuroleptic classifications try to take account of both biological effects (interaction with different neurotransmitters, selectivity of action on dopaminergic structures or dopaminergic subclasses of receptors) and clinical effects (sedative properties, efficacy on positive or negative symptomatology of schizophrenia, antimanic effect). Zotepine blocks mainly dopaminergic, 5-HT 2 and alpha 1 receptors. It should therefore be expected to have sedative properties in humans and to be effective against mania and the positive symptoms of schizophrenia.
D000818:Animals; D014150:Antipsychotic Agents / Q000145:classification / Q000494:pharmacology*; D001058:Apomorphine / Q000494:pharmacology; D001831:Body Temperature / Q000187:drug effects; D003988:Dibenzothiepins / Q000494:pharmacology*; D004298:Dopamine / Q000502:physiology; D004347:Drug Interactions; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000502:physiology; D013239:Stereotyped Behavior / Q000187:drug effects
D014150:Antipsychotic Agents; D003988:Dibenzothiepins; D018377:Neurotransmitter Agents; D001058:Apomorphine; C022172:zotepine; D004298:Dopamine